title: Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging.
abstract: Immune responses wane during aging, posing challenges to the potential effectiveness of cancer immunotherapies. We previously demonstrated that in the context of a promising immunotherapeutic, OX40 agonist (αOX40), older animals exhibited impaired anti-tumor immune responses and diminished CD4 T cell effector differentiation. In this study, we hypothesized that tumor immune responses could be maintained during aging through caloric restriction (CR) or dietary supplementation with resveratrol (RES), a CR mimetic. Mice were placed on either a calorically restricted diet or a RES-formulated diet starting between 4 and 6 months of age and continued until mice reached 12 months of age. Tumor immune responses were assessed after challenging with either sarcoma or breast tumor cells followed by αOX40 treatment. Our results show that CR, but not RES, maintained OX40-mediated anti-tumor immunity. In addition, CR fully sustained antigen-specific CD4 T cell priming in aged hosts (12 months old), whereas tumor-specific CD8 T cell priming was not fully maintained compared to young reference animals (2 months old). Thus, CR appears to maintain immunological fitness of the CD4 T cell priming environment during aging, which is critical for optimal OX40-mediated responses.
authors.affiliation: Department of Immunology/Microbiology, Rush University Medical Center, Chicago, IL, 60612, USA.
authors.forename: Michelle
authors.initials: M
authors.lastname: Farazi
authors.forename: Justine
authors.initials: J
authors.lastname: Nguyen
authors.forename: Josef
authors.initials: J
authors.lastname: Goldufsky
authors.forename: Stephanie
authors.initials: S
authors.lastname: Linnane
authors.forename: Lisa
authors.initials: L
authors.lastname: Lukaesko
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Weinberg
authors.forename: Carl E
authors.initials: CE
authors.lastname: Ruby
mesh_terms: D019264:Adoptive Transfer; D000375:Aging / Q000276:immunology*; D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D015153:Blotting, Western; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D031204:Caloric Restriction; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D009374:Neoplasms, Experimental / Q000276:immunology* / Q000401:mortality / Q000628:therapy; D053262:Receptors, OX40 / Q000819:agonists*; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology*; D015996:Survival Rate; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
chemical_list: D016588:Anticarcinogenic Agents; D053262:Receptors, OX40; D013267:Stilbenes; D000077185:Resveratrol